Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3976-3982

  Mascio, Carmela T M ^a   Chesnel, Laurent ^a   Thorne, Grace ^a   Silverman, Jared A ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN; SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CROSS RESISTANCE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESTRICTION MAPPING; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECALIS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS FAECALIS; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS FAECIUM; VIRUS CULTURE; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; VANCOMYCIN RESISTANCE;

EID: 84903218446     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00124-14     Document Type: Article

References (24)

1. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262. http://dx.doi.org/10.1056/NEJM199401273300406. (Pubitemid 24034138)
2. Bartlett JG. 2002. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346:334-339. http://dx.doi.org/10.1056/NEJMcp011603.
3. Bouza E. 2012. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin. Microbiol. Infect. 18(Suppl 6):5-12. http://dx.doi.org/10.1111/1469-0691.12064.
4. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. 2012. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J. Hosp. Infect. 81:1-14. http://dx.doi.org/10.1016/j.jhin.2012.02.004.
5. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin genevariant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. http://dx.doi.org/10. 1056/NEJMoa051590. (Pubitemid 41770164)
6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307. http://dx.doi.org/10.1086/519265. (Pubitemid 47101025)
7. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590. http://dx.doi.org/10.1086/430311. (Pubitemid 40720807)
8. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. 2007. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 102:2781-2788. http://dx.doi.org/10.1111/j.1572-0241.2007.01539.x. (Pubitemid 350179349)
9. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
10. Mascio CTM, Mortin LI, Howland KT, Van Praagh ADG, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for the treatment of Clostridium difficile. Antimicrob. Agents Chemother. 56: 5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
11. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJC. 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob. Agents Chemother. 56: 1613-1615. http://dx.doi.org/10. 1128/AAC.05655-11.
12. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother. 56:3448-3452. http://dx.doi.org/10.1128/AAC.06257-11.
13. Patino H, Stevens C, Louie T, Bernado P, Friedland I. 2011. Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection, abstr K-205a. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
14. Mascio C, Chesnel L, Thorne G, Silverman J. 2012. CB-183,315 demonstrates low in vitro frequency of spontaneous or multistep resistance in Clostridium difficile, Enterococcus faecalis and E. faecium, abstr. P41, p117. Abstr. 4th Int, Clostridium difficile Symp.
15. Mascio C, Chesnel L, Thorne G, Silverman J. 2013. Surotomycin (CB-183,315) demonstrates rapid bactericidal activity against strains of Clostridium difficile, Enterococcus faecalis and E. faecium subjected to 15 days of serial passage under anaerobic conditions, abstr. F-627. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
16. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic; approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Citron DM, Goldstein EJ. 2011. Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. Diagn. Microbiol. Infect. Dis. 70:554-556. http://dx.doi.org/10.1016/j.diagmicrobio.2011.04.012.
18. Silverman JA, Oliver N, Andrew T, Li T. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802. http://dx.doi.org/10. 1128/AAC.45.6.1799-1802.2001. (Pubitemid 32466351)
19. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, Valiquette L. 2010. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect. Dis. 10: 363-369. http://dx.doi.org/10.1186/1471-2334-10-363.
20. Bolton RP, Culshaw MA. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169-1172. http://dx.doi.org/10.1136/gut.27.10. 1169. (Pubitemid 16002615)
21. Peláez T, Alcalá L, Alonso R, Rodríguez- Créixems M, García-Lechuz JM, Bouza E. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46: 1647-1650. http://dx.doi.org/10.1128/AAC.46.6. 1647-1650.2002. (Pubitemid 34535177)
22. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, Kuijper EJ, Wilcox MH. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62:1046-1052. http://dx.doi.org/10.1093/jac/dkn313.
23. Chesnel L, Sambol S, Gerding D, Patino H, Thorne G, Silverman J. 2012. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and reinfection rates compared with vancomycin. Clin. Microbiol. Infect. 18(Suppl 3):380. http://dx.doi.org/10.1111/j.1469-0691.2012.03802.x.
24. Gilmore MS, Lebreton F, van Schaik W. 2013. Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. Curr. Opin. Microbiol. 16:10-16. http://dx.doi.org/10.1016/j.mib.2013.01.006.